Viewing Study NCT04981028


Ignite Creation Date: 2025-12-26 @ 11:11 AM
Ignite Modification Date: 2026-01-01 @ 2:05 AM
Study NCT ID: NCT04981028
Status: UNKNOWN
Last Update Posted: 2021-08-09
First Post: 2021-07-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: The ConNeCT Study: Neurological Complications of TTP
Sponsor: Liverpool University Hospitals NHS Foundation Trust
Organization:

Study Overview

Official Title: The ConNeCT Study: Neurological Complications of Thrombotic Thrombocytopenic Purpura
Status: UNKNOWN
Status Verified Date: 2021-07
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Thrombotic thrombocytopenic purpura (TTP) is a rare condition, which has a very high risk of death if not recognised and given immediate treatment. TTP is caused by a very low level of an enzyme in the body, called ADAMTS13. A lack of ADAMTS13 causes multiple small clots to form around the body which can disrupt the blood flow to important organs. Although survival has improved significantly, it is now being recognised that patients with TTP may suffer with longer term complications as a result of their condition; literature from the USA reports higher rates of major depression and also poor memory and reduced concentration in patients with TTP. The investigators aim to improve the understanding of the long-term complications and review, for the first time, forward-looking data at multiple time points in patients with TTP in the UK. Both patients with a new diagnosis and patients with a known diagnosis of TTP identified in NHS hospitals will be included, over a minimum duration of 2 years. This will be a questionnaire based study with both doctor led and participant led questionnaires at pre-determined points in time. By improving the understanding and comparing symptoms to that of the general population, the investigators hope to improve the support and tailor the treatments which can be offered to patients with TTP.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: